{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:17:28Z","timestamp":1764260248500,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:00:00Z","timestamp":1662854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease causing systemic thrombotic microangiopathy (TMA) due to the fact of complement dysregulation. Immune activation by viruses, including SARS-CoV-2, can lead to the development of an episode of aHUS against a background of genetic dysregulation in the complement pathway. This paper presents an analysis of two cases of aHUS\u2014siblings diagnosed with familial disease, with a genetic predisposition to aHUS, in whom infection with SARS-CoV-2 was a strong trigger of disease recurrence. The quick recognition and treatment with eculizumab in the early stage of the disease resulted in a rapid improvement in clinical conditions and laboratory parameters.<\/jats:p>","DOI":"10.3390\/ijerph191811437","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T22:53:46Z","timestamp":1663023226000},"page":"11437","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Atypical Hemolytic Uremic Syndrome after SARS-CoV-2 Infection: Report of Two Cases"],"prefix":"10.3390","volume":"19","author":[{"given":"Iwona","family":"Smarz-Widelska","sequence":"first","affiliation":[{"name":"Department of Nephrology, Cardinal Stefan Wyszynski Provincial Hospital, 20-718 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Syroka-G\u0142\u00f3wka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cardinal Stefan Wyszynski Provincial Hospital, 20-718 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Janowska-Jaremek","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cardinal Stefan Wyszynski Provincial Hospital, 20-718 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9079-8594","authenticated-orcid":false,"given":"Ma\u0142gorzata M.","family":"Kozio\u0142","sequence":"additional","affiliation":[{"name":"Chair and Department of Medical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6043-3236","authenticated-orcid":false,"given":"Wojciech","family":"Za\u0142uska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Medical University of Lublin, 20-954 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.4081\/hr.2017.7053","article-title":"Atypical Hemolytic Uremic Syndrome: A Brief Review","volume":"9","author":"Zhang","year":"2017","journal-title":"Hematol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sheerin, N.S., and Glover., E. (2019). Haemolytic uremic syndrome: Diagnosis and management. F1000Research, 8.","DOI":"10.12688\/f1000research.19957.1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and Outcomes of Thrombotic Microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Smarz-Widelska, I., Grywalska, E., Morawska, I., Forma, A., Michalski, A., Mertowski, S., Hrynkiewicz, R., Nied\u017awiedzka-Rystwej, P., Korona-Glowniak, I., and Parczewski, M. (2021). Pathophysiology and Clinical Manifestations of COVID-19-Related Acute Kidney Injury-The Current State of Knowledge and Future Perspectives. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137082"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2020.04.003","article-title":"Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China","volume":"98","author":"Su","year":"2020","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.kint.2020.05.013","article-title":"The case of complement activation in COVID-19 multiorgan impact","volume":"98","author":"Noris","year":"2020","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1111\/jth.15050","article-title":"Is the COVID-19 thrombotic catastrophe complement-connected?","volume":"18","author":"Conway","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(20)30243-5","article-title":"Pulmonary and cardiac pathology in African American patients with COVID-19: An autopsy series from New Orleans","volume":"8","author":"Fox","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00430-021-00704-7","article-title":"An update: The emerging evidence of complement involvement in COVID-19","volume":"210","author":"Li","year":"2021","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaci.2020.05.006","article-title":"Complement activation in patients with COVID-19: A novel therapeutic target","volume":"146","author":"Cugno","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000508920","article-title":"Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era","volume":"144","year":"2020","journal-title":"Nephron"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"4","article-title":"Atypical Hemolytic Uremic Syndrome (aHUS): Treating the Patient","volume":"11","author":"Laurence","year":"2013","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00467-020-04714-0","article-title":"Different approaches to long-term treatment of aHUS due to MCP mutations: A multicenter analysis","volume":"36","author":"Gimpel","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000492865","article-title":"Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury","volume":"48","author":"Cao","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood.2020008248","article-title":"Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., Dong, Q., Zhang, Z., Wang, Z., and Hu, Y. (2020). Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv.","DOI":"10.1101\/2020.03.29.20041962"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/bloodadvances.2021005246","article-title":"C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19","volume":"6","author":"Aiello","year":"2021","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kobbe, R., Schild, R., Christner, M., Oh, J., Loos, S., and Kemper, M.J. (2017). Case report atypical hemolytic uremic syndrome triggered by influenza B. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0512-y"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/MPH.0000000000002036","article-title":"Diagnostic Considerations in H1N1 Influenza-induced Thrombotic Microangiopathy. Rozwa\u017cania diagnostyczne w mikroangiopatii zakrzepowej wywo\u0142anej przez gryp\u0119 H1N1","volume":"44","author":"Sabulski","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.kint.2020.10.030","article-title":"Atypical HUS relapse triggered by COVID-19","volume":"99","author":"Ville","year":"2021","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.ekir.2021.07.004","article-title":"Atypical Hemolytic and Uremic Syndrome Triggered by Infection With SARS-CoV2","volume":"6","author":"Kaufeld","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","article-title":"Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry","volume":"4","author":"Rondeau","year":"2019","journal-title":"Kidney Int. Rep."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/18\/11437\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:29:31Z","timestamp":1760142571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/18\/11437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,11]]},"references-count":26,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijerph191811437"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191811437","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2022,9,11]]}}}